Biomarkers in Prostate Cancers

Dear Colleagues,

Prostate cancer represents a prevalent malignancy among men. The prominent prostate cancer biomarkers encompass prostate-specific antigen (PSA) and its derivatives, which are proteins produced by prostate cells, as well as various genetic markers. These biomarkers play a pivotal role in facilitating the early detection, risk assessment, and monitoring of treatment responses. Recent research endeavors have primarily concentrated on innovative biomarkers capable of distinguishing between aggressive and indolent forms of prostate cancer, thus aiding in treatment decision making. Furthermore, liquid biopsies designed to detect circulating tumor cells or cell-free DNA exhibit a substantial potential for monitoring disease progression and assessing the responses to therapy. Biomarkers, such as the microbiome, miRNA, long non-coding RNAs (lncRNAs), exosomes, and testosterone, may forecasting responses to anticancer treatments, which make them significance in enhancing treatments’ effectiveness and prostate cancer patients’ survival. As our comprehension of the molecular mechanisms underlying prostate cancer advances, the exploration of novel biomarkers has the potential to revolutionize diagnostic and management approaches, ultimately leading to improved patient outcomes.

This Special Issue serves to spotlight the present state of research pertaining to biomarkers in prostate cancer and the future prospects for enhancing diagnosis and treatment.

Prof. Dr. Shigeo Horie
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.